FREDERICK, Md., March 29, 2019 /PRNewswire-PRWeb/ -- RoosterBio, Inc, a leading supplier of innovative human Mesenchymal Stem/Stromal Cell (hMSC) biomanufacturing systems, will attend the Society for Biomaterials Annual Meeting & Exposition on April 3-6, 2019 in Seattle, Washington.
"This conference gives us the opportunity to connect with academic, healthcare, governmental and business professionals in all aspects of the biomaterial science field who are advancing the rapidly growing regenerative medicine industry," said RoosterBio CEO Margot Connor. "RoosterBio's products are accelerating the cell-based bioeconomy by providing standardized hMSCs product platforms that enable rapid clinical and commercial translation. By sharing knowledge at the annual meeting, we can collaborate across various scientific disciplines including materials science, biology, engineering and medicine to improve human health."
RoosterBio Scientist Josephine Lembong, PhD will present a poster at the conference titled, 'Scalable Xeno-Free Microcarrier-based Suspension Bioreactor System for Biomanufacturing of Human Mesenchymal Stem/Stromal Cells (hMSCs) for Regenerative Medicine' (#1067). Poster Sessions will be held on Thursday, April 4, 2019 from 6:30pm to 8:00pm and Friday, April 5, 2019 from 3:45pm to 5:15pm.
Commenting on the poster, Connor added, "The data shown in this presentation demonstrates our robust, scalable hMSC culture process in bioreactors. The consistent cell yield and maintained cell quality exhibited with this scalable fed-batch process allows the adaptation of this plug-and-play standardized system by translational researchers and hMSC product developers in the regenerative medicine, tissue engineering, and cell therapy fields, while providing significant time and cost savings."
Additional meeting details can be located on the conference website at http://www.2019.biomaterials.org.
About RoosterBio, Inc RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.
SOURCE RoosterBio
Advertisement
"This conference gives us the opportunity to connect with academic, healthcare, governmental and business professionals in all aspects of the biomaterial science field who are advancing the rapidly growing regenerative medicine industry," said RoosterBio CEO Margot Connor. "RoosterBio's products are accelerating the cell-based bioeconomy by providing standardized hMSCs product platforms that enable rapid clinical and commercial translation. By sharing knowledge at the annual meeting, we can collaborate across various scientific disciplines including materials science, biology, engineering and medicine to improve human health."
Advertisement
RoosterBio Scientist Josephine Lembong, PhD will present a poster at the conference titled, 'Scalable Xeno-Free Microcarrier-based Suspension Bioreactor System for Biomanufacturing of Human Mesenchymal Stem/Stromal Cells (hMSCs) for Regenerative Medicine' (#1067). Poster Sessions will be held on Thursday, April 4, 2019 from 6:30pm to 8:00pm and Friday, April 5, 2019 from 3:45pm to 5:15pm.
Commenting on the poster, Connor added, "The data shown in this presentation demonstrates our robust, scalable hMSC culture process in bioreactors. The consistent cell yield and maintained cell quality exhibited with this scalable fed-batch process allows the adaptation of this plug-and-play standardized system by translational researchers and hMSC product developers in the regenerative medicine, tissue engineering, and cell therapy fields, while providing significant time and cost savings."
Additional meeting details can be located on the conference website at http://www.2019.biomaterials.org.
About RoosterBio, Inc RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.
SOURCE RoosterBio
